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Background
In rich countries the prevalence of HIV/AIDS among
elderly patients (≥50 years) is increasing as a result of the
extended survival of HIV
+ patients receiving antiretroviral
treatment (HAART), growing new infections and new late
diagnosis. Data about efficacy and tolerability of HAART
in old age are controversial. The aim of this retrospective
study is to evaluate the efficacy of HAART and clinical
outcome in a ≥50 year group of patients compared to a
control group (<50 years old).
Materials and methods
The study population includes all naïve patients treated
with HAART from November 1996 to June 2008 and fol-
lowed in two different units of Infectious disease in Cata-
nia (Sicily). We evaluated the following parameters:
epidemiological (sex, age, risk factors), immuno-virological
(CD4 cell count, HIV RNA viral load), and clinical (CDC
stage, first treatment, number and causes of therapeutic
switch, new AIDS diseases and death).
Results
272 HIV
+ patients were enrolled for the analysis: 212
(78%) male; 121 (44%) heterosexuals, 101 (38%) homo-
bisexuals, 44 (16%) injection drug users; 138 (50%) CDC
A, 32 (12%) CDC B, 102 (38%) CDC C; median CD4
cell count was 163/µl (IQ range 49–322), median HIV-
RNA viral load 5.0 log10 (IQ range 4.3–5.4). Fifty-six
subjects (20.6%) were ≥50 years.
At baseline, among the elderly, the sexual risk was
more frequent than in young (p<0.01); older patients
were also more frequently symptomatic (p = 0.002).
Instead we did not observe any difference as to CD4 cell
count and HIV-RNA copies/ml.
After twelve months of HAART no divergence was
noticed between elderly and younger patients regarding
median absolute increase of the CD4 cell count (+170
vs. +208 cells/μl) and percentage of patients with HIV-
RNA <400 copies/ml (85% vs 83%).
After twenty-four months, a higher number of patients
with HIV-RNA <400 copies/ml (as treated analysis) was
been shown in elderly group (p<0.05). Probability of
first treatment discontinuation (Kaplan Meier analysis),
number and causes of therapeutic switch were similar in
both groups. After a median follow-up of 65 months no
differences were seen regarding new AIDS diseases
whereas elderly patients had a higher probability of
death compared to younger (14.3% vs 4.6%) (p=0.02).
Conclusions
This retrospective study shows a similar immunological
response in elderly and younger naive patients on
HAART. Older patients have a higher probability to
maintain undetectable HIV-RNA viral load (adherence
effect?). However, hard clinical end-points are more fre-
quent in older subjects. Prospective studies are neces-
sary to further investigate our findings.
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